Literature DB >> 2829712

Norfloxacin resistance in a clinical isolate of Escherichia coli.

H Aoyama1, K Sato, T Kato, K Hirai, S Mitsuhashi.   

Abstract

Analysis of DNA gyrase supercoiling and of norfloxacin uptake in Escherichia coli GN14176, a moderately norfloxacin-resistant clinical isolate, indicated that resistance was associated with both an altered drug target and a reduction in drug uptake.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2829712      PMCID： PMC175005          DOI： 10.1128/AAC.31.10.1640

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein.

Authors:  M Gellert; L M Fisher; M H O'Dea
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

2.  Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens.

Authors:  C C Sanders; C Watanakunakorn
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

3.  Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli.

Authors:  K Hirai; H Aoyama; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

4.  Isolation of outer membrane proteins of Escherchia coli and their characterization on polyacrylamide gel.

Authors:  J Uemura; S Mizushima
Journal:  Biochim Biophys Acta       Date:  1975-12-01

5.  Studies on the mechanism of action of nalidixic acid.

Authors:  G J Bourguignon; M Levitt; R Sternglanz
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

6.  Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli.

Authors:  K Sato; Y Inoue; T Fujii; H Aoyama; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

7.  Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.

Authors:  D C Hooper; J S Wolfson; K S Souza; C Tung; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

8.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

9.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

10.  Outer membrane permeation of beta-lactam antibiotics in Escherichia coli, Proteus mirabilis, and Enterobacter cloacae.

Authors:  T Sawai; R Hiruma; N Kawana; M Kaneko; F Taniyasu; A Inami
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191
View more
  35 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandanavia.

Authors:  M Jonsson; M Walder; A Forsgren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

3.  Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid.

Authors:  N Moniot-Ville; J Guibert; N Moreau; J F Acar; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus.

Authors:  K Ubukata; N Itoh-Yamashita; M Konno
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  Interaction of the fluoroquinolone antimicrobial agents ciprofloxacin and enoxacin with liposomes.

Authors:  J Bedard; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.

Authors:  S P Cohen; L M McMurry; S B Levy
Journal:  J Bacteriol       Date:  1988-12       Impact factor: 3.490

7.  Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter.

Authors:  M López-Brea; T Alarcón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

8.  Molecular characterization of an Enterobacter cloacae gene (romA) which pleiotropically inhibits the expression of Escherichia coli outer membrane proteins.

Authors:  T Komatsu; M Ohta; N Kido; Y Arakawa; H Ito; T Mizuno; N Kato
Journal:  J Bacteriol       Date:  1990-07       Impact factor: 3.490

9.  Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of Escherichia coli, Pseudomonas aeruginosa, and Alcaligenes faecalis to ciprofloxacin.

Authors:  J Bedard; S Chamberland; S Wong; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

10.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.